Summary
Signal counts
Assets tracked: 6
Watchlist assets: 5
Registry stop assets: 0
Sponsor overview
Asan Medical Center
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT01187212 | https://clinicaltrials.gov/study/NCT02311205 | https://clinicaltrials.gov/study/NCT05184803 | https://clinicaltrials.gov/study/NCT01487720 | https://clinicaltrials.gov/study/NCT00976768 | https://clinicaltrials.gov/study/NCT04310709
Assets
Linked programs
- Capecitabine/Cisplatin + Sorafenib: Results Not Found Signal (3/5)
- Conventional Transarterial Chemoembolization (TACE): Timeline Staleness Signal (4/5)
- Docetaxel injection, oxaliplatin, S-1: Low Signal (0/5)
- GEMOX: Results Not Found Signal (2/5)
- oxaliplatin, 5-fluorouracil: Results Not Found Signal (3/5)
- Regorafenib/Nivolumab: Results Not Found Signal (2/5)